# First-in-Human Single Ascending Dose of SHR0302

> **NCT02423538** · PHASE1 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 64 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** SHR0302
- **DRUG:** SHR0302 placebo comparator

## Key facts

- **NCT ID:** NCT02423538
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2015-04
- **Primary completion:** 2016-07
- **Final completion:** —
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2016-01-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02423538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02423538, "First-in-Human Single Ascending Dose of SHR0302". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02423538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*